Myocardial Diseases
12
0
0
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (12)
Improved Detection of Myocardial Fibrosis: a Cardiovascular Magnetic Resonance Imaging Study
Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
Troponin T in Chronic Obstructive Pulmonary Disease (COPD) Patients After Physical Exercise
Pediatric Cardiomyopathy Registry
Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States
Enalapril After Anthracycline Cardiotoxicity
Epidemiology of Idiopathic Dilated Cardiomyopathy (Washington, DC Dilated Cardiomyopathy Study)
Genetic Analysis of Familial Hypertrophic Cardiomyopathy
AIDS-Associated Heart Disease -- Incidence and Etiology
AIDS-Associated Cardiomyopathy
HIV-Associated Heart Disease